BioSpace News Archive

Select Medical Holdings Corporation, will release the financial results for its second quarter ended June 30, 2021 on Thursday, August 5, 2021 after the market closes.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced it plans to release its second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the New England Journal of Medicine published results from the Phase 3 HARMONY study, an international, double-blind, placebo-controlled relapse prevention trial in 392 patients evaluating pimavanserin as an investigational treatment in patients with hallucinations and delusions associated with dementia-related psychosis (DRP)

CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter financial and operating results after market close on Wednesday, August 4, 2021

TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 2,617,802 shares of the Company’s common stock at a public offering price of $3.82 per share, less underwriting discounts and commissions.

Ascletis Pharma Inc. (HKEX code: 1672) today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients with recurrent glioblastoma (rGBM).

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that it has received conditional listing approval from the NYSE American LLC stock exchange.

CRB, an international leader in sustainable engineering, architecture, construction and consulting solutions to the food and beverage and life sciences industries, today announced the election of four new members to its Board of Directors.

Paradigm4 has launched its REVEALTM: Multi-Omics app, allowing researchers to undertake advanced, cross-study analyses and enable quick searches for genes and proteins across all integrated public reference and proprietary datasets.

ERYTECH Pharma (Nasdaq & Euronext: ERYP),today announced its intention to move forward towards the submission of a BLA to the US Food and Drug Administration (FDA)for eryaspase in hypersensitive acute lymphoblastic leukemia (ALL) patientsfollowing feedback from the agency in a pre-BLA meeting.